ZebiAI, TB Alliance collaborate on tuberculosis targets

By The Science Advisory Board staff writers

February 2, 2021 -- Biotech firm ZebiAI has announced a collaboration agreement with nonprofit TB Alliance to further the discovery, development, and delivery of tuberculosis drugs.

TB Alliance will provide funds for ZebiAI to develop small molecule probes against key tuberculosis targets. The nonprofit will also have the right to exercise options for further discovery work on each target with ZebiAI.

The partnership is part of ZebiAI's Chemome Initiative, which utilizes the company's proprietary machine-learning algorithms to drive compound discovery, characterize protein function, and validate novel therapeutic targets.

If you like this content, please share it with a colleague!

Related Reading

Synthetic chemistry can help speed protein subunit vaccine development
A new method using synthetic chemistry can be a powerful tool for efficiently building adjuvanted protein-based subunit vaccines against a variety of...

Artificial intelligence helps researchers find new antibiotics
To address antibiotic resistance, researchers have developed a machine-learning approach that can search millions of known chemicals to find new...

New CRISPR system efficiently battles antibiotic resistance
Researchers from the University of California San Diego have developed a brand new CRISPR-based gene-drive system that dramatically increases the efficiency...

Bacterial structures are critical to the development of new antibiotics
A research team from Cornell University have uncovered a unique regulatory mechanism unique to bacterial that may provide crucial insight for antibiotic...

Thermally stable TB vaccine may now be possible thanks to an innovative new process
Researchers at the University of Bath have developed a process that protects vaccines from heat damage by trapping them in silica cages. The results were...